J&J Starts The Year With A Bang With 22 Early-Stage Deals
This article was originally published in The Pink Sheet Daily
Executive Summary
The new collaborations cross the company’s diversified business, with an emphasis in pharma on drug discovery and early-stage research in collaboration with biotech and academia.
You may also be interested in...
Better Late Than Never, J&J’s Innovation Centers Start Opening For Business
J&J’s new London innovation center has just opened and Boston, San Francisco and Shanghai sites are soon to follow. A J&J executive providing an update in NY faced questions from a somewhat skeptical audience of potential customers, revealing nuances and new information about how the centers will operate.
As Seagen Matures, CEO Siegall Talks About Moving The Growth Goalposts
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.
J.P. Morgan, Without The Parties, Reveals An Industry Ready To Get Down To Business
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: